Published in Drug Law Weekly, June 15th, 2004
The trial will use DU.S.A's Levulan photodynamic therapy (PDT) with three light sources, including Cynosure's V-Star pulse dye laser treatment.
"Leading dermatologists consider Levulan PDT one of the most exciting developments impacting their medical and aesthetic practices," said Michael R. Davin, CEO of Cynosure. "As our population ages, the interest in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.